help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bates, A. S.
Right arrow Articles by Clayton, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bates, A. S.
Right arrow Articles by Clayton, R. N.
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 3 818-824
Copyright © 1997 by The Endocrine Society

Endocrinological Oncology

Allelic Deletion in Pituitary Adenomas Reflects Aggressive Biological Activity and Has Potential Value as a Prognostic Marker1

A. S. Bates2, W. E. Farrell, E. J. Bicknell, A. M. McNicol3, A. J. Talbot4, J. C. Broome, C. W. Perrett5, R. V. Thakker6 and R. N. Clayton

Center for Cell and Molecular Medicine, University of Keele School of Postgraduate Medicine (A.S.B., W.E.F., E.J.B., A.J.T., J.C.B., R.N.C.), Stoke-on Trent, United Kingdom ST4 7QB

Address all correspondence and requests for reprints to: Dr. W. E. Farrell, Center for Cell and Molecular Medicine, University of Keele School of Postgraduate Medicine, Stoke-on Trent, United Kingdom ST4 7QB.

Tumors of the pituitary gland are usually benign adenomas and account for 10% of all intracranial neoplasms. Five pituitary tumors have previously been reported to harbor multiple allelic deletions. Of these, three displayed particularly aggressive biological behavior, whereas there were no clinical details provided for the others. This study was designed to test the hypothesis that genetic deletions are a marker of invasive behavior and to identify the loci most commonly involved. Accordingly, we studied two cohorts of pituitary tumors, classified radiologically as invasive or noninvasive, for loss of heterozygosity (LOH).

There is a significantly higher frequency of LOH in invasive tumors (10.8% of all loci examined) compared to noninvasive tumors (2.4%; P < 0.001). Of the 11 loci investigated, 75% of the allelic deletions identified in invasive tumors were found at 4 loci: 11q13, 13q12–14, 10q, and 1p. Twenty of 47 invasive tumors had evidence of at least 1 allelic deletion, whereas 14 of 20 had more than 1. Of the 6 tumors with only 1 deletion, 5 involved the 11q13 locus, suggesting that this is an early change in the transition from noninvasive to invasive adenoma. Comparison of invasive and noninvasive tumors demonstrates a significantly higher frequency of deletions affecting 11q13 (P < 0.001), 13q12–14 (P < 0.05), and 10q26 (P < 0.05) in invasive tumors. In addition, allelic deletion correlates with increasingly invasive behavior (modified Hardy classification), as 73% of grade 4 tumors compared to 33% of grade 3 and 9.5% of grade 1 and 2 tumors demonstrated LOH at any locus. Furthermore, in some tumors we identified a breakpoint between markers intragenic and extragenic to the retinoblastoma gene (Rb1) on chromosome 13q, suggesting that tumor suppressor genes other than or in addition to Rb1 may be involved in pituitary tumorigenesis. This was further supported by the presence of Rb protein in two of four tumors where the genetic loss extended to include the intragenic marker D13S153.

Early identification of tumors with likely invasive potential by means of genetic analysis (LOH) may provide useful information on potential tumor behavior and aid tumor management in a manner that is not possible using routine histological methods. A large prospective study is required in patients without radiological evidence of invasion to assess the value of LOH in predicting outcome and for planning treatment.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
X. Zhu, X. Mao, R. Hurren, A. D. Schimmer, S. Ezzat, and S. L. Asa
Deoxyribonucleic Acid Methyltransferase 3B Promotes Epigenetic Silencing through Histone 3 Chromatin Modifications in Pituitary Cells
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3610 - 3617.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhu, S. L. Asa, and S. Ezzat
Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia
Clin. Cancer Res., April 1, 2008; 14(7): 1984 - 1996.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Matoso, Z. Zhou, R. Hayama, A. Flesken-Nikitin, and A. Yu. Nikitin
Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia
Carcinogenesis, March 1, 2008; 29(3): 620 - 628.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Melmed
Aryl Hydrocarbon Receptor Interacting Protein and Pituitary Tumorigenesis: Another Interesting Protein
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1617 - 1619.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Zhu, K. Lee, S. L. Asa, and S. Ezzat
Epigenetic Silencing through DNA and Histone Methylation of Fibroblast Growth Factor Receptor 2 in Neoplastic Pituitary Cells
Am. J. Pathol., May 1, 2007; 170(5): 1618 - 1628.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Gurlek, N. Karavitaki, O. Ansorge, and J. A H Wass
What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics
Eur. J. Endocrinol., February 1, 2007; 156(2): 143 - 153.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
C. Onofri, M. Theodoropoulou, M. Losa, E. Uhl, M. Lange, E. Arzt, G. K Stalla, and U. Renner
Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
J. Endocrinol., October 1, 2006; 191(1): 249 - 261.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
I. Donangelo, S. Gutman, E. Horvath, K. Kovacs, K. Wawrowsky, M. Mount, and S. Melmed
Pituitary Tumor Transforming Gene Overexpression Facilitates Pituitary Tumor Development
Endocrinology, October 1, 2006; 147(10): 4781 - 4791.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
W E Farrell
Pituitary tumours: findings from whole genome analyses.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 707 - 716.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. Giacomini, M. Paez-Pereda, M. Theodoropoulou, M. Labeur, D. Refojo, J. Gerez, A. Chervin, S. Berner, M. Losa, M. Buchfelder, et al.
Bone Morphogenetic Protein-4 Inhibits Corticotroph Tumor Cells: Involvement in the Retinoic Acid Inhibitory Action
Endocrinology, January 1, 2006; 147(1): 247 - 256.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman
Diagnosis and Management of Pituitary Carcinomas
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3089 - 3099.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Bahar, D. J. Simpson, S. J. Cutty, J. E. Bicknell, P. R. Hoban, S. Holley, M. Mourtada-Maarabouni, G. T. Williams, R. N. Clayton, and W. E. Farrell
Isolation and Characterization of a Novel Pituitary Tumor Apoptosis Gene
Mol. Endocrinol., July 1, 2004; 18(7): 1827 - 1839.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Simpson, A. M. McNicol, D. C. Murray, A. Bahar, H. E. Turner, J. A. H. Wass, M. M. Esiri, R. N. Clayton, and W. E. Farrell
Molecular Pathology Shows p16 Methylation in Nonadenomatous Pituitaries from Patients with Cushing's Disease
Clin. Cancer Res., March 1, 2004; 10(5): 1780 - 1788.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
F Sandrini, L S Kirschner, T Bei, C Farmakidis, J Yasufuku-Takano, K Takano, T R Prezant, S J Marx, W E Farrell, R N Clayton, et al.
PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex
J. Med. Genet., December 1, 2002; 39(12): e78 - 78.
[Full Text] [PDF]

Home page
 CarcinogenesisHome page
D.J. Simpson, A.A. Fryer, A.B. Grossman, J.A.H. Wass, M. Pfeifer, J.M. Kros, R.N. Clayton, and W.E. Farrell
Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas
Carcinogenesis, November 1, 2001; 22(11): 1801 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. J. Simpson, S. J. Frost, J. E. Bicknell, J. C. Broome, A. M. McNicol, R. N. Clayton, and W. E. Farrell
Aberrant expression of G1/S regulators is a frequent event in sporadic pituitary adenomas
Carcinogenesis, August 1, 2001; 22(8): 1149 - 1154.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
U. Pagotto, T. Arzberger, M. Theodoropoulou, Y. Grübler, C. Pantaloni, W. Saeger, M. Losa, L. Journot, G. K. Stalla, and D. Spengler
The Expression of the Antiproliferative Gene ZAC Is Lost or Highly Reduced in Nonfunctioning Pituitary Adenomas
Cancer Res., December 1, 2000; 60(24): 6794 - 6799.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
R. N. Clayton, M. Pfeifer, A. B. Atkinson, P. Belchetz, J. A. H. Wass, E. Kyrodimou, M. Vanderpump, D. Simpson, J. Bicknell, and W. E. Farrell
Different Patterns of Allelic Loss (Loss of Heterozygosity) in Recurrent Human Pituitary Tumors Provide Evidence for Multiclonal Origins
Clin. Cancer Res., October 1, 2000; 6(10): 3973 - 3982.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. E. Turner, Zs. Nagy, M. M. Esiri, A. L. Harris, and J. A. H. Wass
Role of Matrix Metalloproteinase 9 in Pituitary Tumor Behavior
J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2931 - 2935.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
D. J. Simpson, N. A. Hibberts, A. M. McNicol, R. N. Clayton, and W. E. Farrell
Loss of pRb Expression in Pituitary Adenomas Is Associated with Methylation of the RB1 CpG Island
Cancer Res., March 1, 2000; 60(5): 1211 - 1216.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
S. J. Frost, D. J. Simpson, R. N. Clayton, and W. E. Farrell
Transfection of an Inducible p16/CDKN2A Construct Mediates Reversible Growth Inhibition and G1 Arrest in the AtT20 Pituitary Tumor Cell Line
Mol. Endocrinol., November 1, 1999; 13(11): 1801 - 1810.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
N. A. Hibberts, D. J. Simpson, J. E. Bicknell, J. C. Broome, P. R. Hoban, R. N. Clayton, and W. E. Farrell
Analysis of Cyclin D1 (CCND1) Allelic Imbalance and Overexpression in Sporadic Human Pituitary Tumors
Clin. Cancer Res., August 1, 1999; 5(8): 2133 - 2139.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. J. Simpson, J. Magnay, J. E. Bicknell, A. L. Barkan, A. M. McNicol, R. N. Clayton, and W. E. Farrell
Chromosome 13q Deletion Mapping in Pituitary Tumors: Infrequent Loss of the Retinoblastoma Susceptibility Gene (RB1) Locus Despite Loss of RB1 Protein Product in Somatotrophinomas
Cancer Res., April 1, 1999; 59(7): 1562 - 1566.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Yu. Nikitin, M. I. Juarez-Perez, S. Li, L. Huang, and W.-H. Lee
RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice
PNAS, March 30, 1999; 96(7): 3916 - 3921.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
X. Zhang, G. A. Horwitz, A. P. Heaney, M. Nakashima, T. R. Prezant, M. D. Bronstein, and S. Melmed
Pituitary Tumor Transforming Gene (PTTG) Expression in Pituitary Adenomas
J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 761 - 767.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. R. Gadelha, T. R. Prezant, K. N. Une, R. P. Glick, S. F. Moskal II, M. Vaisman, S. Melmed, R. D. Kineman, and L. A. Frohman
Loss of Heterozygosity on Chromosome 11q13 in Two Families with Acromegaly/Gigantism Is Independent of Mutations of the Multiple Endocrine Neoplasia Type I Gene
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 249 - 256.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. A. T. M. Huizenga, P. de Lange, J. W. Koper, R. N. Clayton, W. E. Farrell, A. J. van der Lely, A. O. Brinkmann, F. H. de Jong, and S. W. J. Lamberts
Human Adrenocorticotropin-Secreting Pituitary Adenomas Show Frequent Loss of Heterozygosity at the Glucocorticoid Receptor Gene Locus
J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 917 - 921.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. S. Ward, G. Brenta, M. Medvedovic, and J. A. Fagin
Studies of Allelic Loss in Thyroid Tumors Reveal Major Differences in Chromosomal Instability between Papillary and Follicular Carcinomas
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 525 - 530.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society